Neuronox
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- Payment Terms
- Negotiable
- Production method
- Negotiable
- Shipping / Lead Time
- Negotiable / Negotiable
- Keyword
- Category
- Other Pharmaceutical Chemicals
Medytox Inc.
- Country / Year Established
-
South Korea
/
- Business type
- Others
- Verified Certificate
-
16
| Product name | Neuronox | Certification | - |
|---|---|---|---|
| Category | Other Pharmaceutical Chemicals | Ingredients | - |
| Keyword | - | Unit Size | - |
| Brand name | - | Unit Weigh | - |
| origin | Stock | - | |
| Supply type | - | HS code | - |
Product Information
Neuronox® is a botulinum toxin type A complex (100 Units) pharmaceutical manufactured by Medy-Tox Inc. and officially launched in Korea since 2006.
Throughout the 1980s and 1990s, Clostridium botulinum had been intensively researched by a group of scientists in Korea. In 2000, the scientists established a biotech venture named "Medy-Tox Inc." which specializes in botulinum and its toxins. Following much research on biological, biochemical, immunological and toxicity aspects, botulinum toxin type A has been developed as a biopharmaceutical product.
In 2004 and 2005, Neuronox® has been licensed to famous pharmaceutical companies including Ranbaxy which is one of the biggest generics companies in the world and a Korean pharmaceutical company, CJ Corp., which will launch Neuronox® in the Latin America of more than 50 countries. Furthermore, Q-MED has been the marketing and distributorship partner of Neuronox® for Europe and Japan since early 2007. All these licensing cases show the credibility of Neuronox®
NEURONX®, the First Choice of Botulinum Toxin Type A Pharmaceutical has the best value proposition in terms of its price and quality. Neuronox® is a biosame form of Botox® (Allergan, USA).
B2B Trade
| Price (FOB) | Negotiable | transportation | - |
|---|---|---|---|
| MOQ | Negotiable | Leadtime | Negotiable |
| Payment Options | Negotiable | Shipping time | Negotiable |
- President
- Jung Hyun Ho
- Address
- 10F, 1694-10 Seocho 4-dong, Seocho-gu, Seoul
- Product Category
- Beauty Equipment
- No. of Total Employees
- 501-1000
- Company introduction
-
Medy-Tox, Inc. is a privately held biopharmaceutical company focused on leveraging its proprietary technologies in the microbial toxin area to develop innovative biotech products to diagnose and treat diseases. Mission Our mission is to provide "Biotechnology for Better Life & Health". We strive to significantly improve the "Quality of Life for People". We want to discover, develop, and market innovative biotechnological products from our core competencies with botulinum toxins and other microbial toxins. Vision Our vision is to be "A Supreme Specialty Biopharmaceutical Company" in the world. Our specialty will be "Technology for Toxins as Therapeutics". By 2010, we will be "The Largest Bio-venture in Korea" in terms of market capitalization. By 2012, we will be "A Worldwide Recognized Biotech Company". We strive to be a top-tier biotech company for all people, including customers, shareholders, and employees. In addition, we want to become the most valued company to our society through economic contribution. Overview MEDY-TOX, Inc. was incorporated in May 2000 with the focus on therapeutics and diagnostic pharmaceutical/protein business based on Clostridium bacteria. Medy-Tox's primary business goal is to establish itself as a premier biopharmaceutical company providing botulinum neurotoxin-related pharmaceuticals and therapeutic/diagnostic antibodies throughout the world, utilizing its superior technology and biopharmaceutical science expertise.
- Main Markets
-
Andorra
Hong Kong(China)
Japan
Lebanon
Singapore
- Main Product
Related Products
Skeletal Muscle Relaxants
Phellinus Linteus (Organic)
OPRM1 U2OS β-Arrestin GPCR Assay Kit
Denogan Inj. 1g
Anesthetics and Analgesics
